Business Context and Reporting Period
Company: Delcath Systems, Inc. (DCTH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Delcath is an interventional oncology company focused on treating cancers primary or metastatic to the liver. Its lead product, HEPZATO KIT (approved by the FDA in August 2023), is a drug/device combination for uveal melanoma with hepatic metastases. In Europe, the device-only version, CHEMOSAT, is approved for percutaneous hepatic perfusion. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $85,231 | $37,205 |
| Gross Profit | $73,434 | $31,017 |
| Gross Margin | 86.2% | 83.4% |
| Operating Income (Loss) | $660 | $(12,410) |
| Net Income (Loss) | $2,700 | $(26,386) |
| Cash and Cash Equivalents | $43,454 | $32,412 |
| Short-term Investments | $47,582 | $20,821 |
| Total Liquidity | $91,036 | $53,233 |
| Net Cash Provided by Operating Activities | $22,516 | $(18,681) |
Debt: The company had no outstanding debt as of December 31, 2025, having paid off all debt instruments in 2024.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $2.7 million in 2025, a significant improvement from a net loss of $26.4 million in 2024. This was driven by a 129% increase in revenue and the elimination of interest expense and warrant liability fair value adjustments that impacted the prior year.
- Revenue Growth: Total revenue more than doubled to $85.2 million, primarily due to the commercial expansion of HEPZATO in the U.S. (24 active sites in 2025 vs. 14 in 2024) and continued sales of CHEMOSAT in Europe.
- Expense Increases: Operating expenses rose to $72.8 million from $43.4 million. Research and Development (R&D) expenses increased 111% to $29.2 million due to the initiation of Phase 2 clinical trials for metastatic colorectal and breast cancer. Selling, General, and Administrative (SG&A) expenses increased 47% to $43.5 million due to commercial expansion and higher stock-based compensation.
- Liquidity Position: Total cash and short-term investments increased by approximately $37.8 million to $91.0 million, supported by positive operating cash flow and proceeds from warrant exercises.
Guidance, Outlook, and Risks
Outlook and Clinical Pipeline:
- HEPZATO Expansion: The company is advancing Phase 2 trials for HEPZATO in liver-dominant metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC). Enrollment for mCRC began in Q3 2025, with mBC enrollment expected to begin in Q1 2026.
- CHOPIN Trial Results: Positive Phase 2 results were announced in October 2025 showing that combining CHEMOSAT with immune checkpoint inhibitors significantly improved progression-free survival and overall response rates in uveal melanoma patients compared to CHEMOSAT alone.
- Commercialization: Management expects R&D expenses to increase in the foreseeable future to complete ongoing clinical trials.
Key Risks and Contingencies:
- Capital Requirements: Despite current liquidity, the company notes it may need additional capital to maintain operations and fund future clinical trials. Failure to raise capital could limit commercialization.
- Supply Chain: The company relies on third-party suppliers for critical components, including melphalan. Disruptions in supply could impair commercialization.
- Reimbursement: Commercial success depends on adequate reimbursement from third-party payors. The company entered a National Drug Rebate Agreement (NDRA) with CMS in October 2025, subjecting it to Medicaid rebates and 340B pricing requirements.
- Regulatory: Future clinical trials may fail, or regulatory approvals for new indications may be delayed or denied.
Investor Verification Checklist
- Revenue Sustainability: Verify the rate of site activation for HEPZATO and the impact of the new NDRA/340B pricing on net revenue per unit.
- Cash Burn vs. Runway: Confirm that the $91 million liquidity position is sufficient to fund the expanded Phase 2 clinical trials and commercial operations through the next 12-24 months without dilutive financing.
- Supply Chain Security: Review the status of contracts with melphalan suppliers to ensure no single point of failure exists for the critical drug component.
- Reimbursement Status: Monitor the status of reimbursement applications in key European markets (e.g., NHS England) and the impact of the NDRA on U.S. hospital adoption.
- Stock Repurchase Program: Assess the impact of the $25 million share repurchase program (with $19 million remaining as of year-end) on future liquidity and capital allocation priorities.